Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Efectos de Lactobacillus Plantarum PS128 en niños con TEA

14 de septiembre de 2026 actualizado por: Chang Gung Memorial Hospital

Efectos de Lactobacillus Plantarum PS128 en niños con trastorno del espectro autista

Autism spectrum disorder (ASD) is a neurodevelopmental disorder that can cause significant social, communication and behavioral deficits. Probiotics are regarded as active microorganisms. With sufficient amounts, probiotics can regulate intestinal flora, intestinal permeability, inflammation and antioxidant reactions in the body. These reactions may further promote health, regulate metabolic disease progression and prevent complications. Lactobacillus plantarum PS128 (PS128) was reported to be a psychobiotic in several animal and human studies which modulated the levels of neurotransmitters in different brain areas. This study is to evaluate whether the consumption of PS128 can improve the symptoms of patients with ASD. The current randomized, placebo-controlled trial was conducted to investigate the psychophysiological effects of PS128 in school children with ASD.

Descripción general del estudio

Estado

Terminado

Tipo de estudio

Intervencionista

Inscripción (Actual)

41

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Taoyuan, Taiwán
        • Chang Gung Memorial Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

7 años a 12 años (Niño)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • (1) Age 7 to 12 years old.
  • (2) PS128 group and placebo group: Children with autism spectrum disorder, confirmed by Autism Diagnostic Observation Schedule.
  • (3) Normal control group: Children without autism spectrum disorder.

Exclusion Criteria:

  • (1) Receiving antibiotics within one month.
  • (2) Probiotics used in powder, capsule, or tablet in two weeks (except for Yogurt, Yogurt, Yakult and other related foods).
  • (3) Patients with hepatobiliary gastrointestinal tract who have undergone surgery (except for hernia surgery and appendectomy)
  • (4) Those with special diets (gluten-free, casein-free, high-protein, and ketogenic diet).
  • (5) Those with a history of cancer.
  • (6) Those who are allergic to lactic acid bacteria.
  • (7) Not eligible judged by PI

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: PS128

Subjects will take PS128 capsules every day (2 capsules/day, once) for 12 weeks.

Each PS128 capsule contained >3 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg.

Comparador de placebos: Placebo

Subjects will take placebo capsules every day (2 capsules/day, once) for 12 weeks.

The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose.

Sin intervención: Normal control

Normal control group are enrolled by invitation from the age and gender matched healthy children.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Changes of Total Scores of Social Responsiveness Scale
Periodo de tiempo: Baseline, Week 12 and Week 16

Social Responsiveness Scale can measure the autism clinical severity with the range from 65-260. The lower scores stand for better social responsiveness.

Baseline, Week 12 and Week 16

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Changes of Total Scores of Repetitive Behavior Scale-Revised
Periodo de tiempo: Baseline, Week 12 and Week 16

Repetitive Behavior Scale-Revised is a questionnaire that focuses on repetitive behavior. The score ranges from 0-129. The lower scores stand for lower repetitive behavior.

Baseline, Week 12 and Week 16
Changes of Total Scores of Child Behavior Checklist
Periodo de tiempo: Baseline, Week 12 and Week 16

Child Behavior Checklist is a parents' report questionnaire for behavioral and emotional problems. The score ranges from 0-240. The lower scores stand for better behavioral and emotional regulation.

Baseline, Week 12 and Week 16
Changes of Total Scores of Adaptive Behavior Assessment System
Periodo de tiempo: Baseline, week 12 and Week 16

Adaptive Behavior Assessment System is a parents' report questionnaire for adaptive behavior. The score ranges from 9-171. The higher scores stand for better adaptive behavior.

Baseline, week 12 and Week 16
Changes in Accuracy of Frith-Happe Animation
Periodo de tiempo: Baseline, Week 12 and Week 16

A quick and objective test of Theory of Mind. 8 questions in total, the more correct questions stand for better Social Cognition.

Baseline, Week 12 and Week 16
Changes in Accuracy of Eyes Task
Periodo de tiempo: Baseline, Week 12 and Week 16

An advanced test for Theory of Mind. 43 questions in total, the more correct questions stand for better social skills.

Baseline, Week 12 and Week 16
Changes of Total Scores of Aberrant Behavior Checklist
Periodo de tiempo: Baseline, Week 12 and Week 16

Aberrant Behavior Checklist is a parents' report questionnaire for aberrant behavior. The score ranges from 0-174. The lower scores stand for less aberrant behavior.

Baseline, Week 12 and Week 16
Changes of Total Scores of Emotional Dysregulation Inventory
Periodo de tiempo: Baseline, Week 12 and Week 16

Emotional Dysregulation Inventory is a parents' report questionnaire for emotional dysregulation. The score ranges from 0-120. The lower scores stand for better emotional regulation.

Baseline, Week 12 and Week 16
Changes of Total Scores of Parenting Stress Index, Fourth Editon
Periodo de tiempo: Baseline, Week 12 and Week 16

Parenting Stress Index is a parents' report questionnaire for parenting stress. The score ranges from 0-180. The lower scores stand for lower parenting stress.

Baseline, Week 12 and Week 16
Assessment of Clinical Global Impression-Severity of Illness
Periodo de tiempo: Week 12 and Week 16

The Clinical Global Impression (CGI) is a clinician rated measure of illness severity, improvement, and efficacy of treatment. The CGI-I is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. The score ranges from 1-7. CGI Improvement scale: 1=very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse.

Week 12 and Week 16
Assessment of Patient Global Impression of Change
Periodo de tiempo: Week 12 and Week 16

The self-report measure Patient Global Impression of Change (PGIC) reflects a patient's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a patient's rating of overall improvement. The score ranges from 1-7. Patients rate their change as "1=very much improved ," "2=much improved," "3=minimally improved," "4=no change," "5=minimally worse," "6=much worse," or "7=very much worse)."

Week 12 and Week 16
Gut Microbiota-Relative Abundance of Bifidobacterium Faecale
Periodo de tiempo: Baseline and Week 12

Collect the DNA of fecal flora to test the diversity and abundance of gut microbiota as well as short chain fatty acids in Stool samples. The 16S rRNA gene amplicons will be prepared following the Illumina protocol for preparing the 16S metagenomic sequencing library. Values represent percentages and range from 0 to 100%, with higher values indicating a higher relative abundance of the target bacterium in the gut microbiota

Baseline and Week 12
MRI T1
Periodo de tiempo: Baseline and Week 12

Brain structural volumes (cm²). The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time.

Baseline and Week 12
Functional MRI (Resting-state/Biological Motion Task) - BOLD Signal
Periodo de tiempo: Baseline and Week 12

Blood-oxygen-level-dependent (BOLD) signal is a measurement used in fMRI, which reflects the neural activity. The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time.

Baseline and Week 12
Diffusion Tensor Imaging (DTI) - FA
Periodo de tiempo: Baseline and Week 12

Fractional anisotropy (FA) is a measurement used in DTI, which reflects the movement of water molecules. FA ranges from 0 to 1, the higher FA value may represent more intact axons. The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time.

Baseline and Week 12
Safety Assessment - Albumin
Periodo de tiempo: Baseline and Week 12

Safety is assessed function of liver and kidney such as albumin (3.5-5.4 g/dl).

Baseline and Week 12
Safety Assessment - Total Protein
Periodo de tiempo: Baseline and Week 12

Safety is assessed function of liver and kidney such as total protein (6.4-8.3 g/dl).

Baseline and Week 12
Safety Assessment - ALP
Periodo de tiempo: Baseline and Week 12

Safety is assessed function of liver and kidney such as ALP (135-320 U/L).

Baseline and Week 12
Safety Assessment - Total Bilirubin
Periodo de tiempo: Baseline and Week 12

Safety is assessed function of liver and kidney such as total bilirubin (0.3-1.2 mg/dl).

Baseline and Week 12
Safety Assessment - T-Cholesterol
Periodo de tiempo: Baseline and Week 12

Safety is assessed function of liver and kidney such as T-Cholesterol (<170 mg/dL).

Baseline and Week 12
Safety Assessment - Uric Acid
Periodo de tiempo: Baseline and Week 12

Safety is assessed function of liver and kidney such as uric acid (<7.0 mg/dl).

Baseline and Week 12
Safety Assessment - BUN
Periodo de tiempo: Baseline and Week 12

Safety is assessed function of liver and kidney such as BUN (7-25 mg/dl).

Baseline and Week 12
Safety Assessment - Creatinine
Periodo de tiempo: Baseline and Week 12

Safety is assessed function of liver and kidney such as creatinine (0.2-1.0 mg/dl).

Baseline and Week 12
Safety Assessment - AST
Periodo de tiempo: Baseline and Week 12

Safety is assessed function of liver and kidney such as AST (13-40 U/L).

Baseline and Week 12
Safety Assessment - ALT
Periodo de tiempo: Baseline and Week 12

Safety is assessed function of liver and kidney such as ALT (7-40 U/L).

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - MPO
Periodo de tiempo: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - MPO (ng/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - IL-1β
Periodo de tiempo: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - IL-1β (pg/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - TGF-β1
Periodo de tiempo: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - TGF-β1 (pg/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - Eotaxin
Periodo de tiempo: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - Eotaxin (pg/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - IL-6
Periodo de tiempo: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - IL-6 (ng/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - Serotonin
Periodo de tiempo: Baseline and Week 12

Oxidative stress is assessed via Serotonin (ng/mL).

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - GABA
Periodo de tiempo: Baseline and Week 12

Oxidative stress is assessed via GABA (μmol/L).

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - Cortisol
Periodo de tiempo: Baseline and Week 12

Oxidative stress is assessed via Cortisol (6-10am 4.82-19.5, 4-8pm 2.47-11.9, μg/dl).

Baseline and Week 12
Gut Microbiota-Relative Abundance of Lactiplantibacillus Plantarum
Periodo de tiempo: Baseline and Week 12

Collect the DNA of fecal flora to test the diversity and abundance of gut microbiota as well as short chain fatty acids in Stool samples. The 16S rRNA gene amplicons will be prepared following the Illumina protocol for preparing the 16S metagenomic sequencing library. Values represent percentages and range from 0 to 100%, with higher values indicating a higher relative abundance of the target bacterium in the gut microbiota.

Baseline and Week 12

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

15 de julio de 2022

Finalización primaria (Actual)

3 de abril de 2024

Finalización del estudio (Actual)

3 de abril de 2024

Fechas de registro del estudio

Enviado por primera vez

14 de marzo de 2022

Primero enviado que cumplió con los criterios de control de calidad

24 de marzo de 2022

Publicado por primera vez (Actual)

1 de abril de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

14 de septiembre de 2026

Última verificación

1 de febrero de 2025

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 202101416A3

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir